North American Fragmin Trial


firstslidepreviousslidenextslidelastslide
This slide shows the prophylactic recommendations for prevention of DVT for patients undergoing orthopedic procedures on the lower extremities. These recommendations are based on best medical evidence reviewed by a selected committee of the American College of Chest Physicians. Both Fragmin ® (dalteparin) and Lovenox ® (enoxaparin) are approved for prophylaxis of DVT after hip replacement. The dalteparin dose is 5000 IU daily for at least 7-10 days after surgery. The enoxaparin dose is 30 mg twice a day for at least 7-10 days after surgery.

Antithrombotic
Therapy

Modules

SlideShows

Antithrombotic
Therapy